Rafael Jimenez Nieves

It’s not brain surgery. But we approach telling your brand’s story with the same precision—with 100+ PhDs, MDs, and PharmDs we can call on for unmatched medical expertise. That’s the power of Avant Healthcare + Real Chemistry. #PowerUp #MedicalStorytelling

17

CDMO Nucleus RadioPharma reveals expansions at two sites that will "significantly improve" market access to promising cancer treatments. 🏗️ The upgrades at sites in Mesa, #Arizona and Springhouse, #Pennsylvania will give each facility research, development and commercial production capabilities, boosting capacity by 200%. The expansions are expected to be completed by the end of 2026 and will create around 100 jobs overall. 💉 The upgrades will allow more patients to receive radiopharmaceuticals, which have a limited shelf-life, according to Nucleus. 💬 "To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them," Nucleus RadioPharma CEO Charles Conroy, RPh, MBA said in a release. "Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%." #CDMO #Radiopharmaceuticals #Radiopharma

13

In 2024, 5 emerging BTK inhibitors are undergoing late-phase clinical investigation for #multiplesclerosis. Most clinicians are likely unaware of the clinical data regarding their use in MS. Dive into the data and earn free #CME here: https://bit.ly/4gViIVp #MedEd #FOAMed

2

Your patients should not have to sacrifice their lifestyle to afford their medications. #Biosimilars have the potential to reduce out-of-pocket costs of medicines for treating certain diseases. Consider offering biosimilars as an option, so patients don't have to choose between their medication and their lifestyle. Learn more: https://ogn.llc/6044lurdQ #OrganonBiosimilars #Dermatologists #Oncologists #Immunologists #Rheumatologists #Gastroenterologists #Opthamologists

136

2 Comments

Recognizing the signs and symptoms of chronic myeloid leukemia (CML) is essential for effective management. Early detection and understanding of key indicators play a crucial role in creating appropriate treatment strategies and improving outcomes for individuals with CML. Learn more about CML from the American Cancer Society at https://lnkd.in/eZfjAhe2 #CancerResearch #CancerResearchMonth #NCRM24

3

Explore the Benefits of Screening for Colorectal Cancer (CRC) with the Cologuard® Test. Experts will discuss the importance of screening starting at 45 for average risk patients, the impact that offering choice can have on patient outcomes, and the unique benefits of incorporating a non-invasive test like the Cologuard test in your practice. Watch now bit.ly/4exB7VB

6

Don’t Miss the NACE On-Demand Course: Non-Statin Lipid Management – It’s All About Risk. This CME webcast explores non-statin lipid management for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in high-risk patients. Dr. Jessica Pena delves into case studies, discussing lipid management in primary hypercholesterolemia, diabetes, and with other risk enhancers, utilizing risk calculators to guide therapy decisions. Learn how to navigate guidelines and expert recommendations to choose the right non-statin therapy, including ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran, for optimal patient outcomes. Don’t miss the NACE On-Demand Course: https://bit.ly/3VXlykc

1

Jennifer A. Woyach discusses congress insights from ASH 2024: https://lnkd.in/dSvEVgV4 In this interview she: • Summarizes BTK mutations and their impact on CLL treatment with BTKi • Adresses the impact of toxicity-related BTKi treatment discontinuation on the overall condition of CLL patients • Discusses combination therapy of BTK- and BCL-2 inhibitors in TN CLL patients The full memo inHaematology ASH 2024 SPECIAL ISSUE is coming soon! #ASH24 #Haematology #Hematology #CLL #Research

7

New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare

3

We want to call your attention to a timely new series on AJMC® Peer Exchange® peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on important issues facing today’s managed care professionals. Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel discussion on the use of CDK4/6 inhibitors in high-risk early breast cancer. With insights from renowned experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO, this series covers crucial updates, best practices in managing toxicity profiles, and navigating financial challenges to optimize patient outcomes. Don't miss out on this opportunity to learn about: - Factors influencing decisions to prescribe CDK4/6 inhibitors - Analysis of the monarchE and NATALEE trial results - Sequencing considerations with CDK4/6 inhibitors - Differences in toxicity profiles between abemaciclib and ribociclib - The impact of different endocrine therapies on toxicities Watch the series here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare #CDK46Inhibitors #Oncology #PatientCare #MedicalUpdates

2

Attention Healthcare Providers: Juvenile #arthritis affects thousands of children, causing significant pain and mobility challenges. As prescribers, it's important to stay informed about all available treatment options. #Biosimilars are safe and effective options that have the same treatment risks and benefits as their reference biologics. Biosimilars may offer your patients access to treatment options that could potentially improve their quality of life. Learn more about biosimilars and their benefits: https://bit.ly/3QYF38X

1

HCPs: Early diagnosis is critical in managing a #RareDisease like primary #hyperoxaluria type 1 (PH1). Left undiagnosed, patients are at increased risk for serious downstream health complications. Learn more from Dr. David J. Sas, pediatric nephrologist, in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR

131

Chronic Kidney Disease (CKD) impacts 35.5 million US adults, increasing the risks of heart disease and kidney failure. Alarmingly though, 90% of adults with CKD are unaware of their condition. Dr. Jesse Roach, a leading nephrology strategist and clinician and a member of the DocGo Medical Advisory Board, is advocating for proactive care to raise awareness and address CKD. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit https://lnkd.in/ewkw4HM3 #ProactiveCare #VirtualCare #RemotePatientMonitoring #ChronicKidneyDisease #KidneyHealth

15

Have you heard of Sustainability Transformation? Sustainability Transformation, or “SX,” is an initiative to synchronize social sustainability with corporate sustainability and then implement the necessary management and business transformations to achieve long-term, sustainable improvement in corporate value. This year Daiichi Sankyo in Japan has been jointly selected by the Ministry of Economy, Trade and Industry and the Tokyo Stock Exchange as a “SX brand 2024.” Leading companies that increase their ability to generate sustainable growth resources through SX and realize increased corporate value are selected and recognized as "SX brands." With this selection, our company has been recognized for our ability to link our business strategy and human resources strategy and elevate them into an overall strategy in pursuit of our 2030 vision to "become a leading global health company that contributes to the development of a sustainable society." We have also been recognized for our distinctive efforts to continuously invest in research and development and undertake measures to enhance our human capital, which is the origin of the Daiichi Sankyo group of companies’ value creation. Click to learn more about our sustainability activities. Passion for Innovation. Compassion for Patients.®

34

Inhaled treprostinil is a strong alternative to Ventavis, offering better treatment adherence and persistence for pulmonary hypertension (PH) patients. #StayInformedWithInpharmD

2